This is the classic website, which will be retired eventually. Please visit the modernized instead.
Working… Menu

AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT05617755
Recruitment Status : Recruiting
First Posted : November 15, 2022
Last Update Posted : October 2, 2023
Information provided by (Responsible Party):
Arsenal Biosciences, Inc.

Brief Summary:
This is a multi-center, open-label phase 1 dose escalation trial that uses a modified 3+3 design to identify a recommended phase 2 dose (RP2D) of AB-1015 cell product. Backfill cohorts will enroll additional subjects at doses deemed to be safe for a total enrollment of up to 12 subjects per each backfill cohort on the protocol.

Condition or disease Intervention/treatment Phase
Carcinoma, Ovarian Epithelial Ovarian Neoplasms Fallopian Tube Neoplasms Peritoneal Neoplasms Neoplasms, Glandular and Epithelial Ovarian Diseases Genital Neoplasm, Female Abdominal Neoplasm Recurrence Biological: AB-1015 Phase 1

Detailed Description:

This study is intended for the patients who have been diagnosed with Epithelial Ovarian Cancer that either came back or did not improve after platinum treatments (platinum resistant). The purpose of this study is to test the safety of using a new treatment called Integrated Circuit T (ICT) cells (AB-1015 cells) in patients with ovarian cancer. This treatment has not been approved by the Food and Drug Administration.

The goal of this study is to calculate the maximum tolerated dose of the AB-1015 cells. T cells are part of the immune system that protect the body from infection and may help fight cancer. The T cells given in this study will come from the patient and will have a genetic circuit/logic gate put in them that makes them able to recognize alkaline phosphatase, germ line/placental (ALPG/P) and mesothelin (MSLN), 2 proteins on the surface of tumor cells. These logic-gated T cells may help the body's immune system identify and kill cancer cells while sparing normal healthy tissues from toxicity.

The AB-1015 cells are given intravenously, after completing 3 rounds of conditioning chemotherapy administered over 3 consecutive days. Conditioning chemotherapy prepares the body to receive the AB-1015 cells. If they continue to meet the eligibility criteria, AB-1015 cells will be given to them 2 days after the last conditioning chemotherapy round. A single infusion of the AB-1015 cells will be given to the subject intravenously.

After completion of study treatment, patients are followed with serial measurements of safety, tolerability and response.

This is a research study to obtain new information that may help people in the future.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-label Phase 1 Study to Evaluate the Safety and Efficacy of AB-1015 in Patients With Resistant/Refractory Epithelial Ovarian Cancer
Actual Study Start Date : November 29, 2022
Estimated Primary Completion Date : March 2024
Estimated Study Completion Date : February 2027

Arm Intervention/treatment
Experimental: AB-1015
Patients receive fludarabine and cyclophosphamide intravenously on days -5 to -3. Patients receive a single dose of AB-1015 intravenously on day 0.
Biological: AB-1015
autologous T cell therapy
Other Name: Integrated Circuit T (ICT) cells

Primary Outcome Measures :
  1. Incidence of adverse events and dose limiting toxicities (DLTs) [ Time Frame: Up to 2 years post treatment ]
    Toxicity grading will be evaluated according to the Cancer Therapy Evaluation Program Common Terminology Criteria for Adverse Events version 5.0 and monitoring of adverse events. Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) events will be graded according to the criteria outlined in the protocol.

  2. Maximal tolerated dose of AB-1015 [ Time Frame: Up to 21 days ]
    Will be determined by a 3x3 dose escalation study

Secondary Outcome Measures :
  1. Number of AB-1015 cells [ Time Frame: Up to 1 year post treatment ]
    Number of AB-1015 cells present in patients treatment with AB-1015

  2. Evidence of anti-tumor activity [ Time Frame: Up to 2 years post treatment ]
    Assessed according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1

  3. Co-expression of ALPG and MSLN targets on tumor cells [ Time Frame: Up to 2 years post treatment ]
    Assessment by immunohistochemistry (or similar method)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Recurrent, advanced, platinum resistant ovarian, fallopian tube, and primary peritoneal cancer and must have a histological diagnosis of a high-grade serous histology.
  • a) Platinum resistant disease is defined as progression of disease within six months of platinum regimen.
  • Doubling of cancer antigen 125 (CA-125) level on 2 successive measurements may be considered as meeting the definition of disease progression
  • b) Have received at least 2 lines of prior therapy including a platinum-based regimen if eligible and a poly-ADP ribose polymerase (PARP) inhibitor if BRCA1/2 mutated. No more than 3 lines of prior therapy for the treatment of platinum resistant disease is permitted.
  • Adequate organ function as per protocol definitions.
  • Eastern Cooperative Oncology Group (ECOG) performance status score 0 or 1.
  • Evaluable disease (dose escalation cohorts) or measurable disease (backfill cohorts) at time of enrollment as per protocol definitions.
  • Negative pregnancy test for women of childbearing potential. Women of non-childbearing potential are those who have been surgically sterilized, have medically confirmed ovarian failure, or have not had menses within the past 12 months.

Exclusion Criteria:

  • Cytotoxic chemotherapy within 14 days of time of cell collection.
  • Cytotoxic chemotherapy within 14 days of starting of conditioning chemotherapy.
  • New York Heart Association functional class II-IV cardiovascular disability
  • Clinically significant pericardial effusion
  • Pleural or peritoneal effusion that requires drainage for symptom management within 28 days of screening.
  • Active autoimmune disease requiring immunosuppressive therapy or uncontrolled with treatment.
  • Untreated brain metastasis.
  • Subjects unwilling to participate in an extended safety monitoring period.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT05617755

Layout table for location contacts
Contact: Arsenal Biosciences 650-446-4874

Layout table for location information
United States, California
UCSF Helen Diller Family Comprehensive Cancer Center Recruiting
San Francisco, California, United States, 94158
United States, Illinois
U of Chicago Comprehensive Cancer Center Recruiting
Chicago, Illinois, United States, 60637
United States, Iowa
U of Iowa Health Care Recruiting
Iowa City, Iowa, United States, 52242
United States, Michigan
Barbara Ann Karmanos Cancer Institute Recruiting
Detroit, Michigan, United States, 48201
United States, New York
Roswell Park Comprehensive Cancer Center Recruiting
Buffalo, New York, United States, 14203
United States, Oklahoma
U of Oklahoma, Stephenson Cancer Center Recruiting
Oklahoma City, Oklahoma, United States, 73117
United States, Texas
MD Anderson Cancer Center Recruiting
Houston, Texas, United States, 77030
United States, Washington
U of Washington - Fred Hutchinson Cancer Center Recruiting
Seattle, Washington, United States, 98195
Sponsors and Collaborators
Arsenal Biosciences, Inc.
Layout table for investigator information
Study Director: Arsenal Biosciences Arsenal Biosciences
Layout table for additonal information
Responsible Party: Arsenal Biosciences, Inc. Identifier: NCT05617755    
Other Study ID Numbers: AB-1015-101
First Posted: November 15, 2022    Key Record Dates
Last Update Posted: October 2, 2023
Last Verified: September 2023

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Arsenal Biosciences, Inc.:
ovarian cancer
fallopian tube cancer
primary peritoneal cancer
platinum resistant
Additional relevant MeSH terms:
Layout table for MeSH terms
Ovarian Neoplasms
Carcinoma, Ovarian Epithelial
Peritoneal Neoplasms
Neoplasms, Glandular and Epithelial
Fallopian Tube Neoplasms
Genital Neoplasms, Female
Abdominal Neoplasms
Ovarian Diseases
Endocrine Gland Neoplasms
Neoplasms by Site
Adnexal Diseases
Genital Diseases, Female
Female Urogenital Diseases
Female Urogenital Diseases and Pregnancy Complications
Urogenital Diseases
Urogenital Neoplasms
Genital Diseases
Endocrine System Diseases
Gonadal Disorders
Neoplasms by Histologic Type
Disease Attributes
Pathologic Processes
Digestive System Neoplasms
Digestive System Diseases
Peritoneal Diseases
Fallopian Tube Diseases